

TABLE 1 Patient demographics and characteristics

Variables		Responders	Non Responders	Total
		(101 pts) N (%)	(92 pts) N (%)	(193 pts) N (%)
Age, years	Median (range)	8.2 (0.7–46.5)	8.2 (0.4–39.2)	8.2 (0.4–46.5)
Sex	Female	45 (51.7)	42 (48.3)	87 (100.0)
Age epilepsy onset, years	Median (range)	1.1 (0 – 21.0)	1.2 (0 – 15.5)	1.2 (0 – 21.0)
Duration of epilepsy, years	Median (range)	4.5 (0.2–43.5)	4.5 (0.3–31.0)	4.5 (0.2–43.5)
Type of epilepsy	Focal	25 (42.8)	34 (57.2)	59 (100.0)
	Generalized	48 (58.5)	34 (41.5)	82 (100.0)
	Combined	28 (53.8)	24 (46.2)	52 (100.0)
Type of seizures	Focal*	17 (48.6)	18 (51.4)	35 (100.0)
	SGS*	8 (33.3)	16 (66.7)	24 (100.0)
	GTCS**	32 (72.7)	12 (27.3)	44 (100.0)
	Other GS**	16 (42.1)	22 (57.9)	38 (100.0)
Etiology	Dravet	25 (65.8)	13 (34.2)	38 (100.0)
	Metabolic	0 (0)	3 (100.0)	3 (100.0)
	Unknown	31 (49.2)	32 (50.8)	63 (100.0)
	Immune-Infectious	3 (42.9)	4 (57.1)	7 (100.0)
	Other genetic	19 (57.6)	14 (42.4)	33 (100.0)
	Structural	23 (46.9)	26 (53.1)	49 (100.0)
	AEDs in add-on	≤ 2 AEDs	71 (50.5)	70 (49.5)
	> 2 AEDs	28 (59.6)	19 (40.4)	47 (100.0)
Concomitant AEDs	CBZ	17 (41.5)	24 (58.5)	41 (100.0)
	CLB	93 (51.7)	87 (48.3)	180 (100.0)
	CZP	3 (75.0)	1 (25.0)	4 (100.0)
	ETS	10 (62.5)	6 (37.5)	16 (100.0)
	LEV	1 (25.0)	3 (75.0)	4 (100.0)
	LTG	5 (62.5)	3 (37.5)	8 (100.0)
	LZP	0 (0)	1 (100.0)	1 (100.0)
	NZP	0 (0)	1 (100.0)	1 (100.0)
	PB	11 (52.4)	10 (47.6)	21 (100.0)
	PHT	7 (70.0)	3 (30.0)	10 (100.0)
	VPA	67 (61.5)	42 (38.5)	109 (100.0)
	ZNS	0 (0)	3 (100.0)	3 (100.0)
	RUF	0 (0)	2 (100.0)	2 (100.0)

LCM	4 (80.0)	1 (20.0)	5 (100.0)
TPM	3 (50.0)	3 (50.0)	6 (100.0)
OXC	1 (50.0)	1 (50.0)	2 (100.0)
GVG	0 (0)	1 (100.0)	1 (100.0)

SGS, secondarily generalized seizures; GTCS, generalized tonic clonic seizures; GS, generalized seizures; AEDs, antiepileptic drugs; CBZ, carbamazepine; CLB, clobazam; CZP, clonazepam; ETS, ethosuximide; LEV, levetiracetam; LTG, lamotrigine; LZP, lorazepam; NZP, nitrazepam; PB, phenobarbital; PHT, phenytoin; VPA, valproic acid; ZNS, zonisamide; RUF, rufinamide; LCM, lacosamide; TPM, topiramate; OXC, oxcarbazepine; GVG, vigabatrin. * Patients with focal epilepsy only. ** Patients with generalized epilepsy only.